Medication Options for Weight Loss in Patients with Multiple Comorbidities

Introduction to Weight Loss Medications

The American Gastroenterological Association recommends GLP-1 receptor agonists, such as semaglutide or liraglutide, as the most appropriate medication options for weight loss in patients with morbid obesity, fatty liver disease, hyperlipidemia, and ulcerative colitis, due to their significant weight reduction benefits and potential improvement in liver health and metabolic parameters 1, 2

Lifestyle modifications, including dietary changes and physical activity, remain the cornerstone of treatment for obesity and NAFLD, regardless of medication choice, as recommended by the Clinical and Molecular Hepatology society 3, 4
A Mediterranean diet is recommended, emphasizing vegetables, fruits, whole grains, nuts, fish, olive oil, and minimal simple sugars and red meats, according to the Gastroenterology society 5, 6
Progressive weight loss of less than 1 kg/week is recommended over rapid weight loss to avoid worsening liver inflammation, as suggested by the Clinical and Molecular Hepatology society 3, 4
Physical activity of 150-300 minutes of moderate-intensity exercise per week is recommended even without significant weight loss, as recommended by the Gastroenterology society 5, 6

GLP-1 receptor agonists, such as semaglutide and liraglutide, are the most effective weight loss medications, with 8-21% weight reduction, and may benefit patients with NAFLD by reducing hepatic steatosis, according to the JAMA and Gastroenterology societies 1, 6
Orlistat, a lipase inhibitor, reduces fat absorption and achieves modest weight loss of approximately 2.9 kg at 12 months, as reported by the Annals of Internal Medicine society 7, 8
Naltrexone/bupropion combination achieves approximately 4.8% weight loss at 56 weeks and may be considered as an alternative if other options are not suitable, according to the Clinical Gastroenterology and Hepatology and JAMA societies 2, 1

Weight loss of 5-7% can decrease intrahepatic fat content and inflammation, and weight loss of >10% can improve liver fibrosis in 45% of patients, as suggested by the Clinical and Molecular Hepatology society 3, 4, 10
Weight loss of 5-10% can positively influence lipid levels, and statins remain safe and recommended for managing hyperlipidemia in NAFLD patients, according to the Annals of Internal Medicine and Gastroenterology societies 9, 7, 5, 6

Assess efficacy and safety at least monthly for the first 3 months, then every 3 months, and monitor liver enzymes, lipid profile, and ulcerative colitis symptoms, as recommended by the Clinical Gastroenterology and Hepatology and Gastroenterology societies 2, 5, 6

Rapid weight loss (>1.6 kg/week) may worsen portal inflammation and fibrosis in some patients with NAFLD, and sympathomimetic agents like phentermine should be avoided in patients with cardiovascular disease, as warned by the Clinical and Molecular Hepatology and Clinical Gastroenterology and Hepatology societies 3, 4, 2
All weight loss medications have side effects and limited long-term safety data, and potential drug interactions with medications for ulcerative colitis should be considered, according to the Annals of Internal Medicine and Clinical Gastroenterology and Hepatology societies 9, 7, 2